Wall Street Zen lowered shares of Exagen (NASDAQ:XGN – Free Report) from a hold rating to a sell rating in a report issued on Saturday morning,Wall Street Zen reports.
XGN has been the topic of a number of other reports. B. Riley Financial assumed coverage on shares of Exagen in a research note on Friday, September 11th. They set a “buy” rating and a $12.00 price target on the stock. Weiss Ratings reiterated a “sell (e+)” rating on shares of Exagen in a research note on Wednesday, November 4th. TD Cowen lifted their price objective on shares of Exagen from $10.00 to $11.00 and gave the company a “buy” rating in a research note on Tuesday, October 13th. Canaccord Genuity Group lowered their target price on shares of Exagen from $11.00 to $9.00 and set a “buy” rating on the stock in a report on Wednesday. Finally, BTIG Research restated a “buy” rating and set a $9.00 target price on shares of Exagen in a research report on Wednesday. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Exagen presently has a consensus rating of “Moderate Buy” and a consensus price target of $9.88.
Get Our Latest Stock Analysis on Exagen
Exagen Stock Performance
XGN traded down $0.28 during trading hours on Friday, hitting $4.13. The stock had a trading volume of 3,356,140 shares, compared to its average volume of 581,895. The company’s fifty day simple moving average is $7.71 and its 200 day simple moving average is $5.13. Exagen has a 1 year low of $2.59 and a 1 year high of $9.28. The stock has a market cap of $105.36 million, a PE ratio of -5.51 and a beta of 2.25. The company has a quick ratio of 3.18, a current ratio of 3.46 and a debt-to-equity ratio of 1.73.
Exagen (NASDAQ:XGN – Get Free Report) last released its quarterly earnings data on Tuesday, November 10th. The company reported ($0.25) EPS for the quarter, missing the consensus estimate of ($0.18) by ($0.07). The business had revenue of $18.42 million for the quarter, compared to analysts’ expectations of $18.34 million. Exagen had a negative net margin of 25.14% and a negative return on equity of 125.60%. Equities analysts anticipate that Exagen will post -0.71 earnings per share for the current year.
Insider Activity
In other news, major shareholder Jorey Chernett sold 58,068 shares of the stock in a transaction dated Friday, November 13th. The shares were sold at an average price of $4.08, for a total value of $236,917.44. Following the sale, the insider directly owned 2,529,436 shares of the company’s stock, valued at approximately $10,320,098.88. This represents a 2.24% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO John Aballi sold 34,294 shares of the stock in a transaction dated Friday, October 16th. The stock was sold at an average price of $7.87, for a total transaction of $269,893.78. Following the completion of the sale, the chief executive officer directly owned 805,540 shares in the company, valued at approximately $6,339,599.80. The trade was a 4.08% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last quarter, insiders have bought 100,900 shares of company stock worth $568,660 and have sold 213,063 shares worth $1,084,856. Corporate insiders own 10.40% of the company’s stock.
Institutional Trading of Exagen
Several institutional investors and hedge funds have recently bought and sold shares of XGN. Corient Private Wealth LP bought a new position in Exagen in the 2nd quarter valued at $52,000. Penbrook Management LLC bought a new position in shares of Exagen in the third quarter worth $92,000. Calamos Advisors LLC bought a new position in shares of Exagen in the third quarter worth $94,000. Bank of New York Mellon Corp bought a new position in shares of Exagen in the second quarter worth $97,000. Finally, Empowered Funds LLC bought a new position in shares of Exagen in the third quarter worth $198,000. 75.25% of the stock is currently owned by hedge funds and other institutional investors.
About Exagen
Exagen Inc. is a diagnostics company focused on testing for autoimmune and rheumatic diseases. It develops and provides blood tests intended to help physicians assess and monitor conditions such as systemic lupus erythematosus and other connective tissue diseases. The company’s AVISE test portfolio includes diagnostic and monitoring tests that use proprietary biomarkers to support clinical evaluation. Its offerings are designed to provide information that may help clinicians distinguish among autoimmune conditions and guide patient care.
Further Reading
- Five stocks we like better than Exagen
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Exagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exagen and related companies with MarketBeat.com's FREE daily email newsletter.
